background
clinic
characterist
human
metapneumoviru
hmpv
associ
lower
respiratori
tract
infect
lrti
allogen
hematopoiet
stem
cell
transplant
hsct
well
describ
describ
clinic
cours
eight
hsct
recipi
suffer
hmpv
infect
method
prospect
includ
patient
hmpvassoci
lrti
allogen
hsct
period
year
hmpv
diagnos
multiplex
polymeras
chain
reaction
pcr
bronchoalveolar
lavag
bal
result
eight
patient
hmpvassoci
lrti
identifi
bal
sampl
three
eight
patient
coinfect
pathogen
median
age
patient
year
interquartil
rang
iqr
median
time
posttranspl
day
iqr
patient
chronic
graftversushost
diseas
cgvhd
patient
receiv
immunosuppress
chest
comput
tomographi
ct
scan
show
groundglass
pattern
patient
seven
eight
patient
requir
hospit
due
sever
symptom
hypoxemia
treat
intraven
immunoglobulin
ivig
combin
oral
ribavirin
six
patient
mortal
rate
conclus
hmpvassoci
lrti
allogen
hsct
recipi
uncommon
present
unspecif
respiratori
symptom
groundglass
pattern
ct
scan
coinfect
respiratori
tract
infect
rti
common
reason
consult
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
outpati
clinic
recent
year
new
respiratori
virus
human
metapneumoviru
hmpv
coronavirus
discov
associ
sever
morbid
mortal
immunocompromis
host
hmpv
singlestrand
neg
rna
viru
belong
famili
paramyxovirida
togeth
respiratori
syncyti
viru
rsv
parainfluenza
virus
hmpv
isol
respiratori
sampl
otherwis
healthi
children
upperlow
ul
rti
seroepidemiolog
studi
indic
exposur
adulthood
hsct
recipi
hmpvassoci
lrti
associ
consider
morbid
mortal
clinic
studi
address
clinic
present
risk
factor
clinic
cours
june
june
patient
follow
allogen
hsct
symptom
lrti
examin
comput
tomographi
ct
scan
case
pulmonari
infiltr
underw
bronchoalveolar
lavag
bal
microbiolog
workup
lrti
defin
presenc
cough
dyspnea
andor
pulmonari
infiltr
ct
chest
scan
follow
index
case
hmpv
infect
polymeras
chain
reaction
pcr
hmpv
routin
includ
diagnost
workup
diagnosi
clinic
laboratori
paramet
includ
blood
count
creactiv
protein
immunoglobulin
analyz
reevalu
prospect
week
furthermor
addit
clinic
laboratori
data
collect
chart
retrospect
patient
gave
written
inform
consent
approv
local
institut
review
board
irb
degre
immunodefici
classifi
accord
clinic
laboratori
criteria
describ
previous
patient
allogen
hsct
month
prior
hmpv
diagnosi
acut
graftversushost
diseas
agvhd
grade
leukocyt
count
l
lymphocyt
count
l
recipi
mainten
immunosuppress
drug
cell
b
cell
deplet
month
prior
hmpv
diagnosi
classifi
moder
immunodefici
case
hsct
month
prior
hmpv
diagnosi
cell
b
cell
deplet
month
prior
diagnosi
agvhdgrad
leukopenia
l
lymphopenia
l
hypogammaglobulinemia
gl
immunodefici
classifi
sever
patient
bal
sampl
analyz
establish
multiplex
pcr
assay
respifind
respifind
abl
detect
rna
virus
one
dna
viru
four
bacteria
adenoviru
bordetella
pertussi
chlamydophila
pneumonia
coronaviru
hmpv
influenza
ab
influenza
legionella
pneumophila
mycoplasma
pneumonia
parainfluenza
type
respiratori
syncyti
viru
ab
rhinoviru
infect
control
reason
patient
screen
weekli
nasopharyng
swab
outpati
followup
becam
neg
assay
standard
cytopatholog
workup
bal
sampl
includ
absolut
cell
count
immunophenotyp
lymphocyt
immunostain
rsv
cytomegaloviru
cmv
influenza
viru
standard
bacteriolog
cultur
identifi
bacteria
fungi
mycobacteria
perform
radiolog
workup
ct
imag
analyz
two
independ
radiologist
awar
clinic
find
underli
diseas
posttranspl
immunodefici
statu
imag
compar
retrospect
earlier
later
seri
within
period
time
spss
softwar
packag
http
wwwspsscom
use
calcul
median
interquartil
rang
iqr
use
nonparametr
test
due
nonnorm
data
distribut
june
june
eight
case
hmpvassoci
lrti
identifi
among
patient
undergo
bronchoscopi
bal
lrti
overal
incid
hmpvassoci
lrti
henc
median
time
posttranspl
day
iqr
five
patient
chronic
graftversushost
diseas
cgvhd
four
patient
previous
biopsyproven
bronchiol
obliteran
immunosuppress
prednison
tacrolimu
mycophenol
acid
tabl
six
case
occur
march
april
infect
epidemiolog
relat
could
identifi
contact
exposur
patient
clinic
characterist
diagnosi
present
tabl
perform
score
karnofski
scale
decreas
compar
previou
visit
median
median
diagnosi
dri
cough
fever
commonli
present
patient
respect
diagnosi
wherea
half
patient
present
runni
nose
dyspnea
new
york
heart
associ
nyha
score
ii
diagnosi
median
total
lymphocyt
count
significantli
lower
compar
week
earlier
vs
p
creactiv
protein
crp
level
significantli
higher
vs
mgl
p
hemoglobin
neutrophil
platelet
immunoglobulin
level
remain
unchang
four
week
diagnosi
igg
level
vs
gl
p
reticulocyt
count
increas
vs
p
therapeut
intervent
see
wherea
hemoglobin
neutrophil
lymphocyt
platelet
iga
igm
level
chang
significantli
prior
bal
chest
ct
scan
perform
patient
typic
ct
find
two
patient
shown
fig
although
ct
find
unspecif
viral
infect
groundglass
pattern
opac
frequent
find
detect
patient
nodul
halo
alveolarinterstiti
infiltr
also
common
find
patient
expiratori
imag
perform
patient
air
trap
sign
activ
bronchiol
obliteran
present
time
diagnosi
spirometri
find
indic
drop
median
compar
earlier
spirometri
co
diffus
capac
slightli
reduc
paramet
restor
baselin
level
month
infect
initi
diagnosi
hmpv
infect
coinfect
observ
three
patient
one
rhinoviru
nasopharyng
swab
one
moraxella
catarrhali
bal
one
coronaviru
bal
respect
notabl
outpati
followup
nasopharyng
swab
screen
could
repeatedli
detect
hmpv
patient
initi
coinfect
indic
previou
bal
sampl
fungal
mycobacteri
coinfect
detect
cmv
reactiv
present
find
bal
fluid
summar
tabl
time
diagnosi
hmpv
infect
cytolog
bal
show
predomin
macrophag
lymphocyt
import
note
patient
marrow
aplasia
time
bal
explain
lymphocyt
l
observ
tabl
patient
bal
perform
virolog
diagnosi
unfortun
quantit
differenti
cell
count
done
patient
treat
weekli
intraven
immunoglobulin
ivig
gkg
bodyweight
median
treatment
durat
week
furthermorebas
expert
opinion
bonney
et
al
six
patient
receiv
oral
ribavirin
start
load
dose
mg
first
day
mg
tid
next
day
increas
dosag
everi
day
maximum
dose
mg
tid
reach
median
durat
ribavirin
treatment
day
four
patient
receiv
maximum
dose
median
time
week
treatment
ribavirin
base
decis
treat
physician
depend
clinic
manifest
overal
treatment
well
toler
signific
advers
event
except
requir
red
blood
cell
rbc
transfus
support
need
ribavirintr
patient
due
wellknown
advers
effect
ribavirin
rbc
erythropoiesi
hemoglobin
level
start
decreas
ribavirintr
patient
day
treatment
due
low
hemoglobin
level
associ
symptom
anemia
patient
treat
ribavirin
requir
total
erythrocyt
transfus
seven
eight
patient
requir
hospit
due
poor
clinic
condit
indic
reduc
karnofski
scale
score
dyspnea
nyha
score
iii
chronic
graftversushost
diseas
grade
accord
g
bronchiol
obliteran
biopsyproven
case
prior
diagnosi
hmpv
infect
h
immunosuppress
amount
criteria
sever
immunosuppress
suggest
j
standard
dose
gkg
bodyweight
k
standard
dose
mg
tid
specifi
score
use
decid
requir
hospit
one
patient
number
requir
intens
care
assist
ventil
despit
immedi
treatment
ivig
oral
ribavirin
rapid
respiratori
failur
exhaust
develop
patient
die
day
diagnosi
hmpv
pneumonia
multiorgan
failur
patient
infect
within
day
transplant
surviv
patient
becam
asymptomat
ie
cough
sneez
dyspnea
nyha
scoreii
median
day
seven
eight
patient
discharg
clinic
improv
condit
median
day
treatment
stop
clinic
laboratori
improv
observ
hmpv
longer
detect
nasopharyng
swab
screen
hmpv
nasopharyng
swab
could
longer
detect
median
week
overal
clinic
recoveri
excel
month
infect
indic
karnofski
score
respiratori
recoveri
assess
lung
function
test
reach
time
period
period
year
could
identifi
eight
case
hmpvassoci
lrti
patient
follow
allogen
hsct
found
bal
patient
undergo
bronchoscopi
respiratori
symptom
infiltr
ct
scan
literatur
hmpv
infect
follow
allogen
autolog
hsct
still
scarc
often
incomplet
condit
regimen
remiss
statu
immunosuppress
laboratori
data
clinic
sign
symptom
durat
ill
well
diagnost
microbiolog
method
often
report
prospect
data
show
hmpv
uncommon
even
later
year
transplant
hospit
requir
major
patient
due
reduct
perform
score
drop
lung
function
initi
clinic
sign
hmpv
infect
unspecif
similar
viral
infect
chest
ct
scan
predominantli
show
groundglass
pattern
also
unspecif
common
find
patient
viral
infect
therefor
recommend
bronchoscopi
patient
suffer
lrti
show
groundglass
pattern
ct
scan
allow
search
viral
infect
use
multiplex
pcr
also
concomit
bacteri
infect
short
interv
transplant
infect
intens
immunosuppress
well
preexist
pulmonari
median
alter
like
bronchiol
obliteran
may
affect
clinic
cours
hmpv
well
viral
infect
henc
import
singl
combin
risk
factor
need
examin
larger
studi
outcom
patient
favor
except
one
patient
suffer
hmpv
infect
shortli
transplant
overal
surviv
significantli
lower
mortal
rate
observ
patient
compar
literatur
mortal
rate
report
howev
patient
poor
outcom
suffer
hmpv
infect
occur
within
first
month
posttranspl
tabl
lack
report
infect
later
posttranspl
period
clearli
indic
potenti
underreport
underdiagnosi
center
perform
bal
patient
lower
respiratori
symptom
remark
better
surviv
patient
might
due
earli
diagnosi
improv
net
state
immun
patient
persist
immunosuppress
treatment
cgvhd
orlik
patient
treatment
stop
week
infect
restart
later
due
clinic
relaps
cgvhd
therefor
specul
cgvhd
immunosuppress
treatment
risk
factor
clinic
relev
hmpv
infect
clarifi
treatment
ivig
ribavirin
respons
therapeut
effect
good
outcom
due
lack
control
group
howev
case
report
small
case
seri
describ
favor
outcom
upon
treatment
ribavirin
ivig
ivig
treatment
given
case
amount
hmpvneutral
antibodi
ivig
formul
remain
unclear
random
studi
hmpv
treatment
still
miss
difficult
perform
due
rel
small
case
number
singl
center
recommend
treatment
ribavirin
base
expert
opinion
support
data
vitro
cell
cultur
mous
model
center
use
oral
ribavirin
sever
immunocompromis
patient
hmpv
infect
well
toler
except
hemolysi
need
repetit
rbc
transfus
need
consid
sever
side
effect
henc
care
analysi
potenti
risk
benefit
recommend
make
decis
start
ribavirin
treatment
select
patient
sever
infect
sever
treatment
strategi
describ
literatur
patient
treat
corticosteroid
aerosol
ribavirin
oseltamivir
surviv
limit
studi
rel
small
number
patient
hmpv
lrti
singlecent
approach
lack
proper
control
group
treatment
approach
howev
due
avail
clinic
laboratori
data
includ
lung
function
test
ct
scan
abl
properli
describ
clinic
cours
hmpv
lrti
recipi
allogen
hsct
summari
hmpv
infect
uncommon
allogen
hsct
recipi
even
later
year
transplant
case
seri
patient
suffer
persist
immunosuppress
andor
cgvhd
patient
suffer
respiratori
symptom
groundglass
pattern
ct
scan
recommend
bal
specif
viral
test
patient
treat
ivig
ribavirin
clinic
outcom
hmpv
infect
good
due
ribavirinassoci
hemolysi
drug
need
given
caution
effect
safeti
combin
treatment
ivig
ribavirin
need
assess
prospect
therapeut
trial
